There's still time to register for tomorrow's webinar which is sponsored by PrimaryBid, featuring Zephyr Energy (ZPHR), SpectrumX, Scirocco Energy (SCIR) and Power Metal Resources (POW). Sign up here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 302.10
Bid: 298.10
Ask: 299.20
Change: -7.40 (-2.39%)
Spread: 1.10 (0.37%)
Open: 312.00
High: 312.00
Low: 290.00
Yest. Close: 309.50
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

DHSC Dispute Update

Fri, 21st May 2021 07:00

RNS Number : 3629Z
Novacyt S.A.
21 May 2021

Novacyt S.A.

("Novacyt", the "Company" or the "Group")


DHSC Dispute Update


Paris, France and Camberley, UK - 21 May 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update to its ongoing dispute with the Department of Health and Social Care ("DHSC").


On 9 April 2021, Novacyt announced that it was in dispute with the DHSC in relation to its second supply contract and that this may have a material impact on Q4 2020 revenues. In the same announcement it was also noted that approximately 50% of Q1 2021 revenue was driven by sales to the DHSC. The dispute may now have a material impact on these Q1 2021 revenues from the DHSC.


The Company has taken legal advice in relation to the dispute and believes it has strong grounds to assert its contractual rights.


The information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as amended) as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.


- End -



Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081


SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470


Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000


Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10 ;


FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000 / 


FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48 


About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.


For more information please refer to the website:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Date   Source Headline
16th Sep 20217:00 amRNSProposed accounting treatment of DHSC dispute
13th Sep 20217:00 amRNSAGM voting
1st Sep 202111:30 amRNSLiquidity Agreement and Total Voting Rights
20th Aug 20217:00 amRNSNotice of AGM
18th Aug 20217:00 amRNSHalf Year Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.